Sam Brusco, Associate Editor06.20.23
Owlet, a pioneer in smart baby monitoring, has gained U.S. Food and Drug Administration (FDA) clearance for BabySat, the first medical pulse oximetry device featuring the company’s wire-free sock design.
Owlet specializes in infant health data, having monitored over a million babies. BabySat combines its consumer-first expertise with hospital-grade monitoring accuracy.
“Our mission is to provide caregivers with the right information at the right time to make informed decisions about their baby’s health,” Kurt Workman, Owlet’s CEO and co-founder told the press. “Today, parents whose babies need additional monitoring are sent home with traditional solutions that can be restrictive and more cumbersome for parents. BabySat pushes forward the modernization of hospital-grade technology for at-home use, and underscores our commitment to transforming baby care solutions.”
Available with a prescription, BabySat brings real-time, medical-grade infant monitoring into the home while under physician supervision. Its pulse oximetry tech offers real-time display of the baby’s heart rate and oxygen saturation level, alerting parents when readings fall out of prescribed ranges.
Adding the BabySat device expands Owlet’s portfolio of consumer products. It will be available in the U.S. and is aimed to launch later this year.
Owlet specializes in infant health data, having monitored over a million babies. BabySat combines its consumer-first expertise with hospital-grade monitoring accuracy.
“Our mission is to provide caregivers with the right information at the right time to make informed decisions about their baby’s health,” Kurt Workman, Owlet’s CEO and co-founder told the press. “Today, parents whose babies need additional monitoring are sent home with traditional solutions that can be restrictive and more cumbersome for parents. BabySat pushes forward the modernization of hospital-grade technology for at-home use, and underscores our commitment to transforming baby care solutions.”
Available with a prescription, BabySat brings real-time, medical-grade infant monitoring into the home while under physician supervision. Its pulse oximetry tech offers real-time display of the baby’s heart rate and oxygen saturation level, alerting parents when readings fall out of prescribed ranges.
Adding the BabySat device expands Owlet’s portfolio of consumer products. It will be available in the U.S. and is aimed to launch later this year.